碘油-平阳霉素乳剂加明胶海绵栓塞治疗子宫肌瘤的临床应用

目的探讨碘油．平阳霉素乳剂加明胶海绵栓塞治疗子宫肌瘤的临床应用,了解此方法的疗效、不良反应及并发症。方法采用seldinger技术,对31例子宫肌瘤患者进行选择性子宫动脉栓塞。通过动脉导管注入碘油．平阳霉素乳剂后,以明胶海绵颗粒加强栓塞阻断肌瘤供血。结果血管造影发现子宫肌瘤主要由双侧子宫动脉供血,肌瘤部位血管征象消失,治疗后3～6个月随访结果表明,肌瘤比治疗前缩小35％-75％,临床症状改善,无1例出现严重并发症。结论碘油-平阳霉素乳剂加明胶海绵栓塞治疗子宫肌瘤近期临床效果好,远期疗效尚待观察。     

海绵状血管瘤介入治疗的临床观察

目的评价和分析平阳霉素碘油乳剂肝动脉栓塞治疗海绵状血管瘤的疗效。方法治疗肝海绵状血管瘤20例,瘤体直径6～20cm,采用seldinger技术股动脉插管,导管超选入肝海绵状血管瘤供血动脉后,缓慢灌注平阳霉素碘油乳剂,所有病例术后随访6～18个月。结果肝动脉栓塞后肝海绵状血管瘤碘油沉积良好,临床症状基本消失,CT复诊病变缩小80%4例,病变缩小50%以上12例,缩小50%～30%3例,缩小30%以下1例,未出现严重并发症。结论平阳霉素碘油乳剂肝动脉栓塞治疗海绵状血管瘤创伤小、恢复快、治疗好,严格掌握适应症值得临床推广的。     

平阳霉素-碘油乳剂加明胶海绵栓塞术治疗肝血管瘤18例疗效观察

目的:探讨平阳霉素(PYM)-碘油乳剂加明胶海绵栓塞治疗肝血管瘤的疗效.方法:对18例肝血管瘤患者应用Seldinger技术,行右股动脉穿刺插管,造影后,再超选择至靶血管,用平阳霉素-碘化油乳剂加明胶海绵栓塞治疗.术后随访3～11个月.结果:18例患者均成功实施栓塞治疗.瘤体缩小>50例(55.6%),缩小30%～50%5例(27.8%).缩小<30%2例(11.1%).1例无变化,总有效率83.4%.所有患者治疗后2周临床症状明显改善或消失.无一例严重并发症发生.结论:平阳霉素-碘油乳剂加明胶海绵治疗肝血管瘤疗效确切、安全、创伤小.值得临床进一步推广和应用.     

肝动脉介入栓塞治疗肝脏海绵状血管瘤的疗效观察

目的观察肝动脉介入栓塞治疗肝脏海绵状血管瘤(CHL)的临床效果。方法选取62例CHL患者,采用平阳霉素加碘油与明胶海绵混合液作为栓塞剂注入肝动脉。结果随访所有患者的瘤体均有明显缩小,其中35例患者缩小50%,9例患者瘤体几乎消失,且所有患者均无特殊不良反应及并发症。结论肝动脉介入栓塞治疗肝脏海绵状血管瘤疗效确切,值得推荐使用。     

安定联合杜冷丁治疗肝血管瘤介入治疗术中上腹疼痛的效果分析

肝血管瘤是发生于肝脏的一种良性肿瘤,随着医学的发展,介入治疗广泛应用于临床。它是利用平阳霉素加碘化油的乳剂及明胶海绵颗粒栓塞肿瘤的血管,利用平阳霉素破坏血管内膜而硬化,抑制血管内皮增生,使血管闭塞,血运缺乏,血管瘤缩小或消失。平阳霉素是目前治疗海绵状血管瘤的首选药。     

选择性肝动脉栓塞治疗肝海绵状血管瘤

目的　研究使用平阳霉素碘油乳剂经肝动脉栓塞治疗肝海绵状血管瘤的方法和效果。 方法　对 2 6例肝海绵状血管瘤进行平阳霉素碘油乳剂经肝动脉栓塞治疗 ;将导管超选择插入肝血管瘤的供血动脉 ,以平阳霉素碘油乳剂栓塞 ,男 12例 ,女 14例 ,年龄 2 8～ 6 2岁 ,平均 4 4岁 ,术前均经US、SCT、DSA检查确诊。 结果　所有病例均成功实施了栓塞治疗 ;2 6例中有 2 1例分别于术后 1～ 12个月进行SCT或B超随访 ;瘤体缩小 >5 0 %者 16例 ,>30 %者 4例 ,其中B超随访肿瘤完全消失 1例 ;1例患者肿瘤缩小不明显。全部患者中临床症状消失 18例 ,明显减轻 6例 ,总有效率 92 % (2 4 / 2 6 ) ;术中及术后无严重并发症。 结论　 平阳霉素碘油乳剂经肝动栓塞是治疗肝海绵状血管瘤的安全、有效的首选方法。     

介入栓塞治疗肝海绵状血管瘤疗效分析

目的：探讨介入栓塞肝动脉治疗肝海绵状血管瘤的临床疗效及影像学改变。方法：对13例确诊的肝海绵状血管瘤患者采用Seldinger技术行股动脉穿刺插管,超选择至肿瘤供血动脉,经导管缓慢注入平阳霉素碘化油混悬液,再用明胶海绵和（或）弹簧圈加强栓塞。经B超、CT检查随访1个月～4年,比较治疗前后临床症状及影像学改变。结果：患者临床症状明显减轻或消失,未出现严重并发症。4例病灶完全或基本消失,7例病灶有不同程度缩小,2例病灶大小无明显变化。结论：介入栓塞治疗肝海绵状血管瘤,是一种安全有效的治疗方法。     

介入治疗肝血管瘤

目的　评价平阳霉素与超液态碘化油治疗肝血管瘤的临床疗效。方法　采用 4F或微导管对 10例肝血管瘤的载瘤动脉行平阳霉素与超液态碘化油栓塞 ,并用消毒明胶海绵条或颗粒对载瘤动脉行保护性栓塞 ,并观察栓塞前后瘤体的大小的变化、患者临床症状及并发症情况。结果　栓塞后 10例肝血管瘤均明显缩小 (P <0 0 5 ) ,临床症状缓解 ,无 1例有严重并发症发生。结论　经载瘤动脉注入平阳霉素与超液态碘化油治疗肝血管瘤是一种既安全、疗效又好的方法。     

介入治疗肝血管瘤

目的 评价平阳霉素与超液态碘化油治疗肝血管瘤的临床疗效。方法 采用4F或微导管对10例肝血管瘤的载瘤动脉行平阳霉素与超液态碘化油栓塞，并用消毒明胶海绵条或颗粒对载瘤动脉行保护性栓塞，并观察栓塞前后瘤体的大小的变化、患者临床症状及并发症情况。结果 栓塞后10例肝血管瘤均明显缩小（P＜0．05），临床症状缓解，无1例有严重并发症发生。结论 经载瘤动脉注入平阳霉素与超液态碘化油治疗肝血管瘤是一种既安全、疗效又好的方法。     

血管介入协同手术治疗肌间血管瘤

目的 探讨肌间血管瘤的最佳治疗方法.方法 用介入方法,术前注入平阳霉素碘油并明胶海绵堵塞供血血管后手术切除血管瘤.结果 术中出血少,术后复发率低.结论 血管介入平阳霉素加碘油注射后栓塞主干血管后手术切除血管瘤治疗肌间血管瘤是比较彻底安全的治疗方法.     

Ameliorative effect of ajwain extract on hexachlorocyclohexane-induced lipid peroxidation in rat liver

Effect of ajwain extract on hexachlorocyclohexane-induced oxidative stress and toxicity in rats were investigated. Six groups of rats were maintained for 12 weeks as (1) Control; (2) HCH (300 mg/kg body weight) injected (3) 1% ajwain extract incorporated diet (4)1% ajwain extract incorporated diet + HCH (5) 2% ajwain extract incorporated diet and (6) 2% ajwain extract incorporated diet + HCH. Results revealed that HCH administration lead to an increase in hepatic lipid peroxidation associated with reduction in, levels of glutathione (GSH), activity of superoxide dismutase (SOD), catalase and glucose-6-phosphate dehydrogenase. Prefeeding of ajwain extract resulted in decreased hepatic levels of lipid peroxides and increased GSH, GSH-peroxidase, G-6-PDH, SOD, catalase and glutathione S-transferase (GST) activities. At the same time there was a significant reduction in hepatic levels of HCH-induced raise in lipid peroxides as a result of the prefeeding the extract. Prefeeding of ajwain extract at 1% level to rats injected with HCH reverted the significant changes in catalase, G-6-PDH, GST and -glutamyl transpeptidase. HCH-induced formation of micronuclei in femur bone marrow was also reduced significantly. It was concluded that HCH administration resulted in hepatic free radical stress, causing toxicity, which could be reduced by the dietary ajwain extract.     

Effect of vitamin A on hexachlorocyclohexane (HCH) toxicity in the rat.

1. Technical hexachlorocyclohexane (HCH) depleted hepatic stores of vitamin A in male albino rats to cause secondary vitamin A deficiency. 2. Toxicity of HCH in rats is augmented by dietary vitamin A-deficiency as evidenced by growth retardation, organ hypertrophies and alterations in the serum and liver levels of the marker enzymes of toxicity. 3. Supplementation of dietary vitamin A to the rats either in adequate (2000 IU/kg diet) or in an excess but not hypervitaminotic level (10(5) IU/kg diet) resulted in significant protection against the toxicity of HCH. 4. The activities of the hepatic xenobiotic metabolizing enzymes were generally low (with the exception of glutathione S-transferase) in the vitamin A-deficient rats compared to those of the vitamin A supplemented diet groups. 5. The results indicated that dietary vitamin A influences the response of male albino rats to HCH toxicity possibly by modulating the activities of hepatic xenobiotic metabolizing enzymes.     

阿昔洛韦复乳的研究:大鼠吸收动力学、生物利用度和趋肝性

目的:研究阿昔洛韦(ACV) 复乳的口服生物利用度和肝靶向性。方法:采用高效液相色谱法测定大鼠口服ACV 复乳和普通片剂后的血药浓度和肝组织分布,对试验数据进行药动学分析。药物浓度对时间数据作房室模型和统计矩解析,并求出相应的药动学参数。结果:大鼠口服ACV 复乳对片剂的相对生物利用度为149-8 % ,达峰时间和血浓维持时间明显延迟。血浓经时过程符合二室开放线性药动学模型。血浓峰值附近的肝组织药物分布是片剂的1-62 倍(P<0.1) ,谷值附近是片剂的5-16 倍(P<0.05) 。结论:大鼠口服ACV 复乳可提高生物利用度,并有一定的肝靶向性。     

肝动脉灌注榄香烯乳联合化疗药物治疗原发性肝癌临床研究

目的探讨榄香烯乳联合化疗药物在肝癌介入治疗中的临床疗效和毒副反应。方法将肝癌患者32例随机分两组，榄香烯乳＋5-氟尿嘧啶（5-FU）＋顺铂（DDP）灌注治疗组（治疗组）20例和5-FU＋DDP治疗组12例（对照组）。结果治疗组临床疗效明显优于对照组（P〈0.01），毒副反应小于对照组，患者的生存质量优于对照组。结论榄香烯乳疗效优、毒副作用小，能改善患者的生存质量，值得在肝癌的介入治疗中应用。     

微创治疗高血压脑出血60例临床疗效观察

目的:探讨高血压脑出血微创治疗的临床疗效。方法:将高血压性脑出血的患者分为颅内血肿微创术组(微创组)60例,内科保守治疗组60例,比较两组觉醒时间、重残率、死亡率。结果:微创治疗术后意识恢复时间明显缩短,且神经功能恢复有效率明显提高,重残及病死率显著下降。结论:微创治疗明显优于内科治疗,微创血肿清除术是一种有效治疗高血压性脑出血的方法,可显著改善患者的预后。     

丹参注射液加三磷酸腺苷治疗高血压脑出血的临床观察

目的：评价丹参注射液在急性高血压脑出血中的治疗作用。方法：将受治的３８例高血压病致脑出血患者在常规治疗基础上随机分成２组：丹参加三磷酸腺苷（ＡＴＰ）组（简称丹参组）、氨甲苯酸（ＰＡＭＢＡ）加ＡＴＰ组（简称ＰＡＭＢＡ组）。结果：采用格拉斯哥预后评分（ＧＯＢ）方法,丹参组中恢复良好和中等残疾（ＧＲ加ＭＰ）者占８５．７％,ＰＡＭＢＡ组为４７．０６％。结论：丹参注射液是一种治疗高血压脑出血安全有效的药物。     

Formulation of Polyiodinated Triglyceride Analogues in a Chylomicron Remnant-Like Liver-Selective Delivery Vehicle

Purpose. A formulation methodology for the incorporation of polyiodinated triglyceride (ITG) analogues into a protein-free chylomicron remnant-like emulsion was developed to provide a vehicle for the selective hepatic delivery of these agents for contrast-enhanced X-ray computed tomography (CECT). Methods. Triglyceride emulsions (10% w/v) were prepared at various processing pressures, temperatures and times with a Microfluidizer^® 110-S using different emulsion component proportions to establish processing and compositional parameters in order to afford stable ITG emulsions (ITG-LE) approaching 200 nm mean diameter. Results. Preliminary data indicated that with a formulation composed of 2.4% dioleoyl PC with a cholesterol:DOPC mole ratio of 0.4 emulsified at 14,700 psi, 35°C for 10 min routinely afforded ITG-LE in the desired size range. The elimination of salt and amino acid from the bulk phase enhanced the stability of the ITG-LE. Incorporation of cholesterol into the monolayer was of critical importance in generating a stable emulsion near the targeted size, with a C:DOPC mole ratio of 0.4 producing a size minimum relative to higher or lower C:DOPC values. Conclusions. The ITG analogues can be readily incorporated into stable remnant-like emulsions of relatively uniform particle size. Combination of the unique ITG contrast agent with the remnant-like delivery vehicle demonstrates a high degree of hepatic selectivity in biodistribution studies and offers significant potential for selective hepatic CECT.     

还原型谷胱甘肽对酒精性肝炎患者肝纤维化指标的影响

目的：观察酒精性肝炎患者使用还原型谷胱甘肽治疗后肝纤维化指标的改善情况及临床症状、体征、肝功能的变化。方法：将72例酒精性肝炎患者分成治疗组（37例）和对照组（35例）,对照组给予甘利欣、门冬氨酸钾镁注射液、多种维生素等综合治疗,治疗组在综合治疗的基础上加用还原型谷胱甘肽（1．5g,一日一次）,疗程均为8周。观察治疗前后两组的血清纤维化指标[透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原N端肽（PⅢ-P）、Ⅳ型胶原（C-Ⅳ）]及生化指标[总胆红素（TBIL）、ALT、AST、γ-谷氨酰转肽酶（GGT）]的变化。结果：治疗组在症状、体征、肝功能、血清纤维化的改善方面明显优于对照组,治疗组血清肝纤维化指标与治疗前相比均有明显下降（P〈0．01）,而对照组下降不明显,两组相比有统计学差异（P〈0．01）。结论：还原型谷胱甘肽对酒精性肝炎患者有明显的抗纤维化作用和保肝护肝作用。     

A Method for the Early Evaluation of the Effects of Storage and Additives on the Stability of Parenteral Fat Emulsions

The combination of sedimentation field-flow fractionation (SedFFF) and photon correlation spectroscopy (PCS) is shown to provide a detailed record of the droplet sizes present in fat emulsions commonly used in parenteral nutrition. The technique presented has been used to record size distribution data for a particular emulsion (Liposyn-II), demonstrating its high stability and lot-to-lot uniformity. The technique is also able to demonstrate how additions of small amounts of electrolytes [0.45% (w/v) NaCl, 0.05% (w/v) CaCl₂] tend to destabilize the emulsion, suggesting some caution in the use of total parenteral nutrition (TPN) mixtures. In contrast, a 1:1 mixture with human serum caused no sign of instability in the Liposyn-II. Using the emulsion as a carrier for lipophilic drugs necessitates adding solutions of the drug in nonaqueous solvents, such as DMSO (dimethyl sulfoxide). This solvent's destabilizing effect results in a droplet coalescence that becomes severe after 3–5 days following a 10% (v/v) addition, while a 5% (v/v) addition reaches the same level of coalescence in 10 days.     

Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy

Stabilization of w/o/w emulsion and its application to transcatheter arterial embolization (TAE) therapy are reviewed. W/o/w emulsion was stabilized by making inner aqueous phase hypertonic, addition of chitosan in inner phase, and techniques of phase-inversion with porous membrane. Lipiodol w/o/w emulsion for TAE therapy was prepared by using a two-step pumping emulsification procedure. The procedure is so easy that the emulsion could be prepared even during the surgical operation. The deposition after hepatic arterial administration of the emulsion was detected by an X-ray CT scanner. The concentration of epirubicin hydrochloride (EPI) in liver was increased and its residence was prolonged by encapsulating it in the w/o/w emulsion. The toxic effects of EPI and lipiodol on the normal hepatic cells were reduced. The w/o/w emulsion prepared by us is a suitable formulation for the TAE therapy.